Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Corebridge Financial Inc.

Corebridge Financial Inc. cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 34,652 shares of the biopharmaceutical company’s stock after selling 1,838 shares during the quarter. Corebridge Financial Inc.’s holdings in Regeneron Pharmaceuticals were worth $24,684,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in REGN. FSA Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals during the third quarter worth about $26,000. Truvestments Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $39,000. Rakuten Securities Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 15 shares during the period. OFI Invest Asset Management purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $28,000. Finally, Larson Financial Group LLC raised its holdings in Regeneron Pharmaceuticals by 127.3% during the third quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 28 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ REGN opened at $658.48 on Monday. The stock has a market capitalization of $71.99 billion, a PE ratio of 17.20, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a fifty day moving average of $689.43 and a 200-day moving average of $813.15. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm posted $11.86 earnings per share. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.53%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Analyst Ratings Changes

REGN has been the subject of a number of research analyst reports. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price target for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Citigroup dropped their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. TD Cowen reduced their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Finally, UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.